9 June 2022
Proveca enters an exclusive agreement with Mawdsley Brooks Brazil
Proveca has entered an exclusive agreement with Mawdsley Brooks Brazil, part of global pharmaceutical services provider Mawdsleys, to commercialise and distribute Sialanar® in Brazil. Under the terms of the agreement, Mawdsley Brooks Brazil will have exclusive rights to...
6 June 2022
Rinicare’s SAFE falls reduction technology granted new UK patent
SAFE has been designed to reduce the burden on overstretched clinicians and care home staff by alerting them to pending falls events. A recently published white paper projected that falls amongst older people will increase by 3.9% a year meaning an extra 110,000 older people are...
31 May 2022
Oxford BioTherapeutics to present initial positive data from Phase I trial at ASCO 2022
• Initial data from Phase 1 dose escalation part of the trial, assessing OBT076 in adult patients with advanced solid tumors, indicated that OBT076 was generally well tolerated with no dose-limiting toxicities observed; optimal dose selected at 3.0 mg/kg. • OBT076 showed...
31 May 2022
Trial to assess Acute Kidney Injury risk prediction technology starts at MFT
A pioneering clinical trial of new technology to predict the risk of patients developing Acute Kidney Injury (AKI) has begun at Manchester University NHS Foundation Trust (MFT). The STABILITY UO (Urine Output) clinical risk prediction technology has been developed by Manchester...
30 May 2022
NIHR backed AI care planning network goes live
English healthcare providers are now able to join a network that uses crowd sourced data to shape care plans. Healum, an artificial intelligence-based App, uses data that patients have chosen to share in order to personalise care recommendations and improve clinical decision...
26 May 2022
Oxford BioTherapeutics announces collaboration with Agenus
Oxford BioTherapeutics announces collaboration with Agenus to support the clinical development of OBT’s antibody drug conjugate OBT076 in combination with Agenus’ CPI Balstilimab … • New deal enables Oxford BioTherapeutics (OBT) to evaluate OBT076 with a checkpoint...
26 May 2022
CARB-X receives additional $370m from U.S. Government and Wellcome
Funding will enable continued investment in innovative projects to tackle the growing global threat posed by AMR … Alderley Park, Cheshire, U.K – Infex Therapeutics, a leader in critical-priority infectious diseases, welcomes the news that CARB-X (Combating Antibiotic...
25 May 2022
Blueberry Therapeutics provides regulatory update on Phase 2b trial
Alderley Park, 24 May 2022 – Blueberry Therapeutics has reported significant progress in its Phase 2b European trial of BB2603 in onychomycosis (BBTAF202). The COVID-19 pandemic led to operational challenges in all 3 participating countries (Germany, Poland and Czech...
17 May 2022
Infex Therapeutics receives MHRA approval to initiate Phase 1 study for RESP-X programme
MHRA grants approval of Phase 1 clinical trial, expected to start in H2 2022 … Alderley Park, Cheshire, U.K – Infex Therapeutics, a leader in critical-priority infectious diseases, is pleased to announce it has received approval from the UK Medicines and Healthcare...
16 May 2022
Maxwellia appoints Ian Adamson as Strategic Advisor
Maxwellia has appointed Ian Adamson as strategic advisor to shape the next phase of pharmacy medicine launches – a process which involves identifying and converting suitable prescription only medicines into versions people can choose to buy under the supervision of a...